Psychedelics company Tryp Therapeutics Inc. (OTCQB: TRYPF) and Harvard’s largest medical teaching facility, the Massachusetts General Hospital (MGH) have inked a Letter of Intent (LOI) to fund and conduct a Phase 2a clinical trial assessing the effects of psilocybin-assisted psychotherapy in the treatment of adult patients with Irritable Bowel Syndrome (IBS.) 

Tryp is a clinical-stage biotech company developing IV-infused therapies based on the magic mushroom components for a variety of health conditions with unmet medical needs as is the case with IBS – a common, chronic and often debilitating condition affecting almost 4-5% of the total population. A large number of IBS sufferers find no relief in current treatments. 

The planned study will evaluate the effect of psilocybin-assisted therapy in …

Full story available on Benzinga.com